These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 23013306)

  • 1. Applicability of fibroblast growth factor 23 for evaluation of risk of vertebral fracture and chronic kidney disease-mineral bone disease in elderly chronic kidney disease patients.
    Kanda E; Yoshida M; Sasaki S
    BMC Nephrol; 2012 Sep; 13():122. PubMed ID: 23013306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for hip and vertebral fractures in chronic kidney disease: the CRIC study.
    Hsu S; Bansal N; Denburg M; Ginsberg C; Hoofnagle AN; Isakova T; Ix JH; Robinson-Cohen C; Wolf M; Kestenbaum BR; de Boer IH; Zelnick LR
    J Bone Miner Res; 2024 May; 39(4):433-442. PubMed ID: 38477777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship between urinary kidney injury molecule-1 and blood bone metabolism markers in patients with chronic kidney disease
.
    Yin C; Cheng C; Wang J; Zhang L; Purrunsing Y; Yang G; Zeng M; Huang H; Ren W; Ye Y; Ma H; Xing C; Wang N
    Clin Nephrol; 2020 Feb; 93(2):65-76. PubMed ID: 31793871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations of fibroblast growth factor 23, vitamin D and parathyroid hormone with 5-year outcomes in a prospective primary care cohort of people with chronic kidney disease stage 3.
    Shardlow A; McIntyre NJ; Fluck RJ; McIntyre CW; Taal MW
    BMJ Open; 2017 Aug; 7(8):e016528. PubMed ID: 28838895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibroblast growth factor 23 and new-onset chronic kidney disease in the general population: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study.
    De Jong MA; Eisenga MF; van Ballegooijen AJ; Beulens JWJ; Vervloet MG; Navis G; Gansevoort RT; Bakker SJL; De Borst MH
    Nephrol Dial Transplant; 2021 Jan; 36(1):121-128. PubMed ID: 32124925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of tubular reabsorption of phosphate as a surrogate marker for phosphate regulation in chronic kidney disease.
    Hong YA; Lim JH; Kim MY; Kim Y; Yang KS; Chung BH; Chung S; Choi BS; Yang CW; Kim YS; Chang YS; Park CW
    Clin Exp Nephrol; 2015 Apr; 19(2):208-15. PubMed ID: 24682550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations of FGF23 With Change in Bone Mineral Density and Fracture Risk in Older Individuals.
    Isakova T; Cai X; Lee J; Katz R; Cauley JA; Fried LF; Hoofnagle AN; Satterfield S; Harris TB; Shlipak MG; Sarnak MJ; Ix JH;
    J Bone Miner Res; 2016 Apr; 31(4):742-8. PubMed ID: 26590361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FGF23 and Left Ventricular Hypertrophy in Children with CKD.
    Mitsnefes MM; Betoko A; Schneider MF; Salusky IB; Wolf MS; Jüppner H; Warady BA; Furth SL; Portale AA
    Clin J Am Soc Nephrol; 2018 Jan; 13(1):45-52. PubMed ID: 29025789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study.
    Pavik I; Jaeger P; Ebner L; Wagner CA; Petzold K; Spichtig D; Poster D; Wüthrich RP; Russmann S; Serra AL
    Nephrol Dial Transplant; 2013 Feb; 28(2):352-9. PubMed ID: 23129826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deviations from the expected relationship between serum FGF23 and other markers in children with CKD: a cross-sectional study.
    Liu D; Alvarez-Elías AC; Wile B; Belostotsky V; Filler G
    BMC Nephrol; 2017 Jun; 18(1):204. PubMed ID: 28659167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibroblast Growth Factor 23 and Risk of CKD Progression in Children.
    Portale AA; Wolf MS; Messinger S; Perwad F; Jüppner H; Warady BA; Furth SL; Salusky IB
    Clin J Am Soc Nephrol; 2016 Nov; 11(11):1989-1998. PubMed ID: 27561289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphate, fibroblast growth factor 23 and retinopathy in chronic kidney disease: the Chronic Renal Insufficiency Cohort Study.
    Mehta R; Ying GS; Houston S; Isakova T; Nessel L; Ojo A; Go A; Lash J; Kusek J; Grunwald J; Wolf M;
    Nephrol Dial Transplant; 2015 Sep; 30(9):1534-41. PubMed ID: 25910495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diagnosis and treatment of osteoporosis in patients with chronic kidney disease : Joint guidelines of the Austrian Society for Bone and Mineral Research (ÖGKM), the Austrian Society of Physical and Rehabilitation Medicine (ÖGPMR) and the Austrian Society of Nephrology (ÖGN)].
    Cejka D; Wakolbinger-Habel R; Zitt E; Fahrleitner-Pammer A; Amrein K; Dimai HP; Muschitz C
    Wien Med Wochenschr; 2023 Oct; 173(13-14):299-318. PubMed ID: 36542221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperphosphatemia with elevated serum PTH and FGF23, reduced 1,25(OH)
    Kritmetapak K; Losbanos L; Berent TE; Ashrafzadeh-Kian SL; Algeciras-Schimnich A; Hines JM; Singh RJ; Kumar R
    BMC Nephrol; 2021 Mar; 22(1):114. PubMed ID: 33784965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease.
    Stubbs JR; He N; Idiculla A; Gillihan R; Liu S; David V; Hong Y; Quarles LD
    J Bone Miner Res; 2012 Jan; 27(1):38-46. PubMed ID: 22031097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral Calcitriol Use, Vertebral Fractures, and Vitamin K in Hemodialysis Patients: A Cross-Sectional Study.
    Fusaro M; Cianciolo G; Tripepi G; Plebani M; Aghi A; Politi C; Zaninotto M; Nickolas TL; Ferrari S; Ketteler M; La Manna G; Gasperoni L; Messa P; Ravera M; Gallieni M; Cosmai L; Locatelli F; Iervasi G; Vettor R; Mereu MC; Sella S; Arcidiacono G; Giannini S
    J Bone Miner Res; 2021 Dec; 36(12):2361-2370. PubMed ID: 34622481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal Evolution of Markers of Mineral Metabolism in Patients With CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study.
    Isakova T; Cai X; Lee J; Mehta R; Zhang X; Yang W; Nessel L; Anderson AH; Lo J; Porter A; Nunes JW; Negrea L; Hamm L; Horwitz E; Chen J; Scialla JJ; de Boer IH; Leonard MB; Feldman HI; Wolf M;
    Am J Kidney Dis; 2020 Feb; 75(2):235-244. PubMed ID: 31668375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Race and Ethnicity Predict Bone Markers and Fracture in Pediatric Patients With Chronic Kidney Disease.
    Laster M; Denburg M; Okuda Y; Kumar J; Furth S; Warady B; Kalantar-Zadeh K; Norris K; Salusky IB
    J Bone Miner Res; 2021 Feb; 36(2):298-304. PubMed ID: 32960469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression of arterial stiffness is associated with changes in bone mineral markers in advanced CKD.
    Krishnasamy R; Tan SJ; Hawley CM; Johnson DW; Stanton T; Lee K; Mudge DW; Campbell S; Elder GJ; Toussaint ND; Isbel NM
    BMC Nephrol; 2017 Sep; 18(1):281. PubMed ID: 28870151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.